Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, T-Cell 2Oligodendroglioma 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Inflammatory Breast Neoplasms 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioblastoma 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1Astrocytoma 1

Interventions

Cyclophosphamide 5Trastuzumab 4Taxes 4Docetaxel 4Paclitaxel 3Albumin-Bound Paclitaxel 3tipifarnib 2sargramostim 2liposomal doxorubicin 2Vorinostat 2Immunohistochemistry 2Granulocyte-Macrophage Colony-Stimulating Factor 2Filgrastim 2Enzyme-Linked Immunosorbent Assay 2Doxorubicin 2Capecitabine 2temsirolimus 1seviteronel 1romidepsin 1poly(I).poly(c12,U) 1pertuzumab 1pegfilgrastim 1oblimersen 1ixabepilone 1interferon gamma-1b 1flt3 ligand protein 1denileukin diftitox 1cixutumumab 1alvocidib 1Vaccines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms, Male × Depsipeptides × Clear all
NCT01938833 2025-05-16

Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer

Thomas Jefferson University

Phase 1/2 Terminated
9 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡